Specialty injectable is a high cost drug therapy that requires administration by injection, inhalation or infusion. This medication is indicated in treatment of chronic or life threatening diseases such as HIV, rheumatoid arthritis, hemophilia, cancer, cardiovascular diseases, infectious diseases, auto immune disorders, and other diseases.
Increasing prevalence of chronic diseases such as cancer and cardiovascular diseases is a major factor driving the specialty injectable generics market growth. According to The National Cancer Institute, 2013, there are over 100 different types of cancers that can be described from the type of cells they are formed from. According to the American Cancer Society, 2017, cancer is the second most common cause of death in the U.S., which accounts for nearly 1 out of every 4 deaths.
Moreover, expiration of the patents of majority of pharmaceutical and biotech products in the near future, especially in high value U.S. and Europe market is boosting the market growth.
However, stringent regulatory guidelines and low profit margins and drug shortage is expected to hamper growth of the global specialty injectable generics market. The shortages faced in the industry are primarily due to increased manufacturing issues, delay in supply, and shortage of Active Pharmaceutical Ingredients (API).
- This report provides in-depth analysis of the specialty injectable generics market and provides market size (US$ million) and Compound Annual Growth Rate (CAGR %) for the forecast period (2018 – 2026), considering 2017 as the base year
- It elucidates potential revenue opportunities across different segments and explains attractive investment proposition matrices for this market
- This study also provides key insights about market drivers, restraints, opportunities, new product launches or approval, market trends, regional outlook, and competitive strategy adopted by key players
- It profiles key players in the global specialty injectable generics market based on the following parameters – company overview, financial performance, product portfolio, market presence, distribution strategies, key developments, strategies, and future plans
- Key companies covered as a part of this study include, Pfizer, Inc., Teva Pharmaceutical Industries Ltd., Novartis AG, Baxter International Inc., Mylan N.V., Fresenius SE & Co. KGaA, Endo International Plc., Hikma Pharmaceuticals PLC, Lupin Ltd., Sagent Pharmaceuticals, Inc., Cipla Limited , Sun Pharmaceutical Industries Limited, and Dr. Reddy's Laboratories
- Insights from this report would allow marketers and the management authorities of the companies to make informed decisions regarding their future product launches, technology up-gradation, market expansion, and marketing tactics.
- The global specialty injectable generics market report caters to various stakeholders in this industry including investors, suppliers, product manufacturers, distributors, new entrants, and financial analysts
- Stakeholders would have ease in decision-making through various strategy matrices used in analyzing the specialty injectable generics market
-
-
- Oncology
- Cardiovascular Diseases
- Central Nervous System Diseases
- Infectious Diseases
- Auto-immune Disorders
- Others
-
- Hospital Pharmacies
- Retail Pharmacies
- Online Pharmacies
-
- North America
- Latin America
- Brazil
- Argentina
- Mexico
- Rest of Latin America
- Europe
- Germany
- U.K.
- Spain
- France
- Italy
- Russia
- Rest of Europe
- Asia Pacific
- China
- India
- Japan
- Australia
- South Korea
- ASEAN
- Rest of Asia Pacific
- Middle East
- GCC Countries
- Israel
- Rest of Middle East
- Africa
- South Africa
- North Africa
- Central Africa
-
- Pfizer, Inc.
- Teva Pharmaceutical Industries Ltd.
- Novartis AG
- Baxter International Inc.
- Mylan N.V.
- Fresenius SE & Co. KGaA
- Endo International Plc.
- Hikma Pharmaceuticals PLC
- Lupin Ltd.
- Sagent Pharmaceuticals, Inc.
- Cipla Limited
- Sun Pharmaceutical Industries Limited
- Reddy's Laboratories
